In The News: School of Integrated Health Sciences
It’s training that’s been in use for generations.
Resverlogix Corp., a world leader in epigenetics, or gene regulation, announces today new data that demonstrates their first-in-class oral small molecule BET inhibitor candidate Apabetalone significantly improves cognition and reduces cognitive decline among high-risk patients with cardiovascular disease and diabetes mellitus.
UNLV launched new Occupational Therapy program that trains students in a home instead of a classroom or lab.
Right now you can nab a fantastic deal on the vitamins and supplements you need to get over the proverbial hump.
When you hit the gym hard, it can be tempting to load up on every shiny tub of mysterious purple powder you can get your hands on in hopes it’ll turn you into vintage Schwarzenegger overnight.
Mary Ashley Galan-Gornal grasped the adaptive knife in her right hand, placed the red delicious apple securely in the vise, and sliced off a piece of the fruit.
Approval of aducanumab will herald a new era in Alzheimer’s disease care and research.
The Food and Drug Administration’s controversial June 7 approval of aducanumab (Aduhelm) means that for the first time in 18 years, Alzheimer’s patients have a new treatment option.
NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced yesterday it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen’s lead compound, NVG-291, in validated animal models of Alzheimer’s disease.
NervGen Pharma Corp., a clinical stage biotech company dedicated to creating innovative solutions for the treatment of nervous system damage, announced today it has entered into a research collaboration with Dr. Ksenia Kastanenka of Massachusetts General Hospital (MGH) to study the effects of NervGen's lead compound, NVG-291, in validated animal models of Alzheimer's disease.
The Food and Drug Administration’s approval of Biogen and Eisai’s anti-amyloid antibody aducanumab on June 7 left many questions unanswered, including how to use the drug in clinical practice.
Many doctors appear uneasy about prescribing Aduhelm, as they continue to grapple with a long list of unknowns.